VRTX241011C460000
- 7.80
- +6.55+524.00%
Vertex Pharmaceuticals Newsroom
Vertex Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $480
Leerink Partners Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $600
DBS Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Buy Rating Affirmed for Vertex Pharmaceuticals on Promising Pain Management Drug Prospects
Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $425
Vertex Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Vertex Pharmaceuticals (VRTX) and Edwards Lifesciences (EW)
DBS Initiates Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Raises Target Price to $502
Wolfe Research Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $518
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $518 From $576, Maintains Outperform Rating
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Vertex Pharmaceuticals Analyst Ratings
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Raises Target Price to $474
Maintaining Hold Rating on Vertex Pharmaceuticals Amidst LSR Trial Uncertainties
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Analyst Ratings